These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34995796)

  • 1. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.
    Gabe MBN; Skov-Jeppesen K; Gasbjerg LS; Schiellerup SP; Martinussen C; Gadgaard S; Boer GA; Oeke J; Torz LJ; Veedfald S; Svane MS; Bojsen-Møller KN; Madsbad S; Holst JJ; Hartmann B; Rosenkilde MM
    Pharmacol Res; 2022 Feb; 176():106058. PubMed ID: 34995796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.
    Skov-Jeppesen K; Svane MS; Martinussen C; Gabe MBN; Gasbjerg LS; Veedfald S; Bojsen-Møller KN; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    Bone; 2019 Aug; 125():178-185. PubMed ID: 31100534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study.
    Skov-Jeppesen K; Hepp N; Oeke J; Hansen MS; Jafari A; Svane MS; Balenga N; Olson JA; Frost M; Kassem M; Madsbad S; Beck Jensen JE; Holst JJ; Rosenkilde MM; Hartmann B
    J Bone Miner Res; 2021 Aug; 36(8):1448-1458. PubMed ID: 33852173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
    Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
    Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
    J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.
    Skov-Jeppesen K; Christiansen CB; Hansen LS; Windeløv JA; Hedbäck N; Gasbjerg LS; Hindsø M; Svane MS; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1773-1780. PubMed ID: 38217866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
    Naylor J; Suckow AT; Seth A; Baker DJ; Sermadiras I; Ravn P; Howes R; Li J; Snaith MR; Coghlan MP; Hornigold DC
    Biochem J; 2016 Sep; 473(18):2881-91. PubMed ID: 27422784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A; Aihara E; Christe ME; Varga G; Beyer TP; Ruan X; Beebe E; O'Farrell LS; Bellinger MA; Austin AK; Lin Y; Hu H; Konkol DL; Wojnicki S; Holland AK; Friedrich JL; Brown RA; Estelle AS; Badger HS; Gaidosh GS; Kooijman S; Rensen PCN; Coskun T; Thomas MK; Roell W
    Cell Metab; 2024 Jul; 36(7):1534-1549.e7. PubMed ID: 38878772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
    Lafferty RA; Flatt PR; Gault VA; Irwin N
    J Endocrinol; 2024 Aug; 262(2):. PubMed ID: 38861364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
    Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
    Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.